Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab, Balstilimab and Regorafenib in MSS mCRC
NCT05672316Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botensilimab, balstilimab and regorafenib in colorectal cancer (CRC), sponsored by City of Hope. Primary endpoints: Recommended Phase 2 Dose at 6 weeks, Dose Limiting Toxicities at 6 weeks and 1 more. Started May 2023; status: active, not recruiting.
02
Drugs
botensilimabbalstilimabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05672316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672316.